Health · Medical Research · 3 hrs ago
Nipocalimab Benefits Sustained for Two Years in Teens With Myasthenia Gravis
Two-year results found nipocalimab’s benefits continued in adolescents with myasthenia gravis.
The findings came from the phase III Vibrance-MG study, which evaluated the drug in this group.
Myasthenia gravis is the condition named in the study; the available information does not describe its symptoms or the results in further detail.
Nipocalimab is also known by the name Imaavy.
Sustained benefits over two years matter because they show the study’s reported effects did not fade during that period.
The results were presented at an annual medical meeting, and no further next steps were specified.
Two-year results from the phase III Vibrance-MG study showed that nipocalimab’s benefits were sustained in adolescents with myasthenia gravis.
The results were presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting.
Nipocalimab is also known as Imaavy.
- Who
- Adolescents with myasthenia gravis.
- What
- Two-year study results showed sustained benefits of nipocalimab.
- When
- The results were presented at the annual meeting; the date is not stated in the article text provided.
- Where
- The American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting.
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Treatment
- Nipocalimab, also known as Imaavy
- Study
- Phase III Vibrance-MG
- Duration
- Two-year results
- Participants
- Adolescents with myasthenia gravis
- Presentation
- American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting
Sources
Related news
Pope Leo has surgery scheduled to remove a lung nodule
New childhood obesity definition focuses on health effects, not BMI alone
GLP-1 drugs did not significantly change injection frequency for diabetic eye disease
Diabetes affects 7.5% of adults in Italy, with cases rising over 20 years
Large study finds abrupt shifts in health markers at menopause
One brain-training session briefly improved mood in a small depression trial
Review finds insufficient evidence for medicinal cannabis to treat insomnia
Study finds existing food preferences can hinder learning new associations
Study links early-onset Alzheimer’s to health problems before diagnosis
A transfer RNA may help restore drug sensitivity in prostate cancer
Small trials suggest semaglutide may reduce some measures of alcohol use
